IBI-Ag’s first and foundational technology platform is based on single domain antibodies, also known as nanobodies, derived through proprietary in vivo immunization processes.
Nanobodies are among the smallest functional antibody fragments in nature. Their compact structure confers exceptional binding affinity, stability, and versatility, properties that make them well-suited as bioinsecticide active ingredients.
How It Works
Step 1
Target Identification
IBI-Ag maintains a proprietary bank of validated protein targets within insect pests. Targets are selected for their functional importance to the insect’s biology and their suitability for antibody-based intervention.
Step 2
Nanobody Library Generation
Nanobody libraries are generated through in vivo immunization against selected target proteins, producing a diverse pool of candidate binders.
Step 3
Screening & Selection
Candidates are screened for binding affinity, selectivity, and biophysical properties.
Step 4
Validation
Selected nanobodies are validated in insect bioassays, confirming efficacy against target pest species.
Built for Performance.
Proven in the Field.
IBI-Ag’s nanobodies combine high target-binding affinity with a compact structure that enables flexible formulation, strong environmental stability, and applicability across a broad range of insect pest species, backed by a validated development pathway with demonstrated results.